Patrick M Sweeney & Associates Inc. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,100 shares of the company’s stock, valued at approximately $631,000.
A number of other institutional investors also recently bought and sold shares of the company. Xponance Inc. purchased a new position in shares of Novo Nordisk A/S in the third quarter worth approximately $248,000. Stratos Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $237,000. Bank of New York Mellon Corp increased its stake in shares of Novo Nordisk A/S by 97.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 863,598 shares of the company’s stock worth $78,536,000 after purchasing an additional 425,392 shares in the last quarter. Brown Advisory Inc. raised its holdings in Novo Nordisk A/S by 96.0% in the 3rd quarter. Brown Advisory Inc. now owns 107,860 shares of the company’s stock worth $9,809,000 after purchasing an additional 52,830 shares during the period. Finally, Miracle Mile Advisors LLC lifted its position in Novo Nordisk A/S by 100.0% during the third quarter. Miracle Mile Advisors LLC now owns 3,346 shares of the company’s stock valued at $304,000 after purchasing an additional 1,673 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.
Novo Nordisk A/S Price Performance
NVO traded down $0.60 during trading on Wednesday, hitting $126.69. 3,250,143 shares of the company traded hands, compared to its average volume of 4,823,868. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The company has a market cap of $568.53 billion, a PE ratio of 43.89, a P/E/G ratio of 1.93 and a beta of 0.43. The stock’s 50-day simple moving average is $127.33 and its two-hundred day simple moving average is $113.50. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28.
Analyst Ratings Changes
Check Out Our Latest Stock Report on Novo Nordisk A/S
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
- Five stocks we like better than Novo Nordisk A/S
- Which Wall Street Analysts are the Most Accurate?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- What is a Secondary Public Offering? What Investors Need to Know
- Generac Powers Ahead on the Electrification Mega-Trend
- How to Use Stock Screeners to Find Stocks
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.